Rare NGR1 Fusion Market Size, Share & Demand Report By Diagnosis Type (Next-Generation Sequencing, Fluorescence In Situ Hybridization (FISH), Polymerase Chain Reaction (PCR)), By Application (Lung Cancer Diagnostics, Solid Tumor Profiling, Hematologic Malignancies), By End User (Hospitals, Diagnostic Laboratories, Cancer Research Institutes), By Technology Platform (DNA Sequencing, RNA Sequencing, Multiplex Assays), By Region & Segment Forecasts, 2026–2034
USD 3950
Market Overview
The Rare NGR1 Fusion Market size is estimated at USD 1.14 billion, and it is projected to reach USD 3.02 billion by 2034, registering a CAGR of 12.9% during 2026–2034. A major global factor supporting the growth of the Rare NGR1 Fusion Market is the increasing implementation of next-generation sequencing (NGS) technologies for rare gene fusion detection in oncology diagnostics. Healthcare providers and pharmaceutical companies are increasingly investing in molecular profiling programs to identify rare genetic alterations associated with targeted therapy eligibility.
The market is further benefiting from expanding research in companion diagnostics, rising approvals of targeted therapies, and increasing awareness regarding personalized cancer treatment pathways. Growing investments in rare cancer therapeutics are also contributing to long-term market expansion.
Key Highlights
- Highest share region (2025): North America – 41.3%
- Fastest-growing region CAGR (2026–2034): Asia Pacific – 14.1%
- Leading subsegment (Diagnosis Type): Next-Generation Sequencing – 2025 share 58.6%
- Fastest-growing subsegment (Application): Lung Cancer Diagnostics – CAGR 14.5%
- Dominant country (2024): United States – USD 0.39 billion
- Dominant country (2025): United States – USD 0.44 billion
Market Trends
Expansion of Precision Oncology Programs
A major trend shaping the Rare NGR1 Fusion Market is the expansion of precision oncology initiatives across hospitals and cancer research institutions. Healthcare providers are increasingly integrating genomic testing into routine oncology workflows to improve identification of rare molecular alterations and guide targeted treatment decisions.
Rising Development of Companion Diagnostics
Another notable trend in the Rare NGR1 Fusion Market is the growing collaboration between pharmaceutical companies and diagnostic developers for companion diagnostic solutions. These partnerships are supporting faster identification of eligible patient populations and improving targeted therapy adoption rates.
Market Drivers
Increasing Adoption of Molecular Testing in Oncology
The growing use of molecular diagnostics in cancer care is significantly driving the Rare NGR1 Fusion Market. Oncologists are increasingly relying on advanced sequencing technologies to identify rare gene fusions and personalize treatment strategies for patients with resistant or advanced-stage cancers.
Rising Pipeline of Targeted Therapies
The increasing number of targeted therapy candidates focused on rare gene fusions is accelerating market growth. Pharmaceutical companies are investing heavily in fusion-targeted oncology drugs to improve treatment outcomes and address unmet clinical needs in precision medicine.
Market Restraint
High Cost of Genomic Testing and Targeted Treatments
One major restraint in the Rare NGR1 Fusion Market is the high cost associated with comprehensive genomic testing and personalized targeted therapies. Limited reimbursement coverage in several developing healthcare systems continues to restrict wider adoption.
Market Opportunities
Growth in Liquid Biopsy Technologies
The expansion of liquid biopsy diagnostics presents strong opportunities for the Rare NGR1 Fusion Market. Non-invasive testing technologies are improving accessibility for rare fusion detection while reducing the need for surgical tissue biopsy procedures.
Increasing Clinical Trial Activity for Rare Cancers
Growing clinical research focused on rare cancers and molecular subtypes is creating new opportunities for market participants. Pharmaceutical companies are increasing investments in biomarker-specific clinical trials to accelerate regulatory approvals and therapy commercialization.
Segmental Analysis
By Diagnosis Type
The Rare NGR1 Fusion Market is segmented into next-generation sequencing, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), and immunohistochemistry. Next-generation sequencing dominated with a 58.6% share in 2025 due to its ability to detect multiple gene fusion alterations with high accuracy and efficiency.
The fastest-growing subsegment is liquid biopsy-based sequencing diagnostics, projected to grow at a CAGR of 14.7% (2026–2034) due to increasing demand for minimally invasive cancer testing solutions.
By Application
Applications include lung cancer diagnostics, solid tumor profiling, hematologic malignancies, and precision oncology research. Lung cancer diagnostics accounted for 46.9% share in 2025 within the Rare NGR1 Fusion Market, driven by increasing identification of rare fusion mutations in non-small cell lung cancer patients.
Precision oncology research is expected to be the fastest-growing subsegment, projected at a CAGR of 14.3%, supported by rising biomarker-focused clinical trial programs.
By End User
End users include hospitals, diagnostic laboratories, cancer research institutes, and specialty oncology clinics. Diagnostic laboratories held 39.4% share in 2025 due to growing outsourcing of advanced genomic testing services.
Cancer research institutes are projected to grow at the fastest CAGR of 13.9% during the forecast period due to increasing investments in rare cancer genomics studies and translational medicine research.
By Technology Platform
Technology platforms include DNA sequencing, RNA sequencing, multiplex assays, and hybrid capture technologies. RNA sequencing dominated with 42.8% share in 2025 due to its effectiveness in detecting gene fusion transcripts across multiple cancer types.
Hybrid capture technologies are projected to grow at the fastest CAGR of 14.2%, driven by improved sensitivity and broader biomarker detection capabilities in oncology diagnostics.
| Diagnosis Type | Application | End User | Technology Platform |
|---|---|---|---|
|
|
|
|
Regional Analysis
North America
North America accounted for 41.3% share of the Rare NGR1 Fusion Market in 2025, supported by advanced oncology research infrastructure and high adoption of genomic sequencing technologies. The region is expected to grow at a CAGR of 12.3% (2026–2034). The United States dominates due to strong investments in precision medicine programs and increasing targeted therapy approvals.
Europe
Europe held 28.1% share in 2025, driven by expanding molecular diagnostics adoption and supportive cancer research initiatives. The region is projected to grow at a CAGR of 12.5% (2026–2034). Germany leads the regional market due to increasing genomic testing integration across oncology centers and hospital networks.
Asia Pacific
Asia Pacific captured 20.7% share in 2025 and is projected to grow at the fastest CAGR of 14.1% (2026–2034) in the Rare NGR1 Fusion Market. China remains the dominant country due to rising cancer prevalence, expanding sequencing infrastructure, and increasing investments in precision oncology research.
Middle East & Africa
Middle East & Africa accounted for 5.4% share in 2025, with a projected CAGR of 11.6% (2026–2034). Growth is supported by improving cancer diagnostic capabilities and rising healthcare modernization initiatives. The UAE leads the region due to increasing investments in advanced oncology treatment facilities.
Latin America
Latin America represented 4.5% share in 2025 and is projected to grow at a CAGR of 11.8% during 2026–2034. Brazil dominates the regional market due to increasing adoption of molecular cancer diagnostics and expansion of private oncology healthcare services.
| North America | Europe | APAC | Middle East and Africa | LATAM |
|---|---|---|---|---|
|
|
|
|
|
Competitive Landscape
The Rare NGR1 Fusion Market is highly innovation-driven, with biotechnology firms, molecular diagnostic companies, and pharmaceutical manufacturers focusing on targeted therapy development and advanced genomic testing platforms. Companies are actively investing in companion diagnostics, biomarker discovery, and clinical trial expansion to strengthen their oncology portfolios.
Key market participants include Roche Holding AG, Illumina Inc., Thermo Fisher Scientific Inc., Guardant Health, and Foundation Medicine. Roche Holding AG remains a leading company in the market due to its broad oncology diagnostics portfolio and strategic collaborations in precision medicine. Market participants are increasingly focusing on AI-driven genomic interpretation and integrated diagnostic platforms to improve detection efficiency for rare fusion mutations.
Key Players List
- Roche Holding AG
- Illumina Inc.
- Thermo Fisher Scientific Inc.
- Guardant Health
- Foundation Medicine
- Qiagen N.V.
- NeoGenomics Laboratories
- Exact Sciences Corporation
- ArcherDX
- Agilent Technologies Inc.
- Bio-Rad Laboratories Inc.
- Caris Life Sciences
- Invitae Corporation
- Natera Inc.
- BGI Genomics
Recent Developments
- 2025: Multiple biotechnology companies expanded clinical trials targeting rare fusion-positive cancers.
- 2025: Roche Holding AG strengthened its precision oncology portfolio through new companion diagnostic collaborations.
- 2024: Guardant Health launched enhanced liquid biopsy testing solutions for rare molecular fusion detection.
- 2024: Illumina Inc. expanded oncology sequencing platforms with improved fusion analysis capabilities.
- 2024: Thermo Fisher Scientific introduced upgraded molecular testing workflows for oncology laboratories.
- 2024: Several cancer institutes increased investment in AI-supported genomic interpretation systems.
- 2024: Pharmaceutical companies accelerated biomarker-focused oncology drug development partnerships.
